Tuesday, 17 November 2026European Markets

GENSIGHT BIOLOGICS Stock Went Down By Over 32% In The Last 21 Sessions

Automated market report from our archive (2020-2024), published before source-traceability. How we work

Loading stream...

(vianews) - shares of gensight biologics (cac 40: sight.pa) dropped by a staggering 32.65% in 21 sessions from €3.4 to €2.29 at 13:59 est on thursday, after three successive sessions in a row of losses. cac 40 is rising 1.11% to €6,962.11, following the last session's downward trend.

about gensight biologics

gensight biologics s.a., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. the company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. its lead product candidates include lumevoq (gs010), a recombinant aav2-based gene therapy, which is in phase iii clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated nd4 gene; and gs030, which is in phase i/ii clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. the company also develops products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. gensight biologics s.a. was incorporated in 2012 and is headquartered in paris, france.

earnings per share

as for profitability, gensight biologics has a trailing twelve months eps of €-0.968.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, gensight biologics's stock is considered to be overbought (>=80).

volume

today's last reported volume for gensight biologics is 44263 which is 75.59% below its average volume of 96138.

more news about gensight biologics (sight.pa).

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

Not a source? Spotted an error? Report an error

How this story was made

  1. Published before we listed source documents with each article.
  2. Published 16 Mar 2023
  3. No responses yet from the people or organisations in this story. Are you in this story? Respond on the record ›
  4. Part of the Via News record, fingerprinted daily so it cannot be quietly rewritten. What that means › · Report an error ›